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These results are consistent with
numerous reports indicating that ErbB
receptors are capable of mediating sig-
naling from a variety of heterologous
stimuli (Carpenter, 1999). Heterologous
ErbB receptor activation can involve
either growth factor ligand-dependent or
-independent mechanisms, but result in
MAP kinase activation via processes
that are most often dependent on recep-
tor tyrosine kinase activity. For example,
transactivation of EGF receptors by 
G protein-coupled receptors (GPCRs)
such as the lysophosphatidic acid (LPA)
receptor has been demonstrated to
induce the shedding of membrane-teth-
ered EGF-like ligand precursors by met-
alloproteases (Gschwind et al., 2001).
Cytokine receptors such as those for
growth hormone and IL6 can interact
with the EGF receptor and ErbB2,
respectively, to mediate MAPK activation
in response to their ligands. Finally,
membrane depolarization and cellular
stresses such as exposure to UV irradia-
tion or oxidants can also lead to MAP
kinase activation through the EGF recep-
tor (Weiss et al., 1997).
The observations of Liu et al. are
also consistent with the emerging theme
that overexpression of some cell surface
proteins could unmask or augment their
ErbB activation activities. For example,
the mucins MUC1 and MUC4 play roles
in the normal protection and lubrication
of epithelial surfaces, but are commonly
found overexpressed in a variety of
malignant tumors. Because their size
and highly negative charge disrupt cell-
cell and even cell-protein interactions,
mucins are thought to contribute to tumor
cell evasion of immune surveillance.
However, both MUC1 and MUC4 have
been shown to interact with ErbB recep-
tor family members and to potentiate sig-
naling (Schroeder et al., 2001) and cellu-
lar growth properties (Komatsu et al.,
2001). While the physiological signifi-
cance of this functional duality in normal
tissue development or maintenance
remains to be determined, aberrant ErbB
activation by overexpressed mucins
could actively contribute to the growth or
progression of tumor cells (Carraway et
al., 2001). Like uPAR, the mucins appear
to exert their effects on ErbB receptors in
the absence of RTK overexpression.
The results described above encom-
pass dozens of individual reports and
emphasize that there is remarkable
plasticity in the activation of the ErbB
RTKs. ErbB activation mechanisms
appear to be more prevalent in tumor
cells that overexpress some heterolo-
gous cell surface proteins, but ErbB
receptor overexpression is not neces-
sary. Hence, it is quite likely that aber-
rant ErbB receptor activation plays a
more far-reaching role in tumor growth
and progression than is represented by
overexpression. Moreover, most of the
described mechanisms involve the acti-
vation of receptor tyrosine kinase activity
itself, as opposed to crossphosphoryla-
tion of receptors by other kinases to
serve as a scaffold for the initiation of
signaling events. These observations
suggest that ErbB-directed tyrosine
kinase inhibitors such as the small mole-
cule EGF receptor inhibitor Iressa, which
in preclinical studies exhibits some
growth inhibitory effects toward EGF
receptor-overexpressing non-small cell
lung cancers (Raben et al., 2002), could
possibly impact a wider subset of tumors
than those that overexpress receptors.
For the future it will be important to deter-
mine the extent to which ErbB receptors
are aberrantly activated in tumors where
overexpression is not observed. The
development of highly sensitive phos-
pho-specific antibodies directed toward
active receptors could help alleviate
some of the technical barriers in this
regard.
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Myc—Is this the oncogene from Hell?
A new paper implicates the Myc oncoprotein in the direct induction of DNA damage and consequent genome instability in
cultured cells. However, it is less clear whether Myc induces the same genetic pandemonium in vivo.
The corrupted genomes of most human
epithelial cancers are, like the Yucatan
crater formed by the meteor that wiped
out the dinosaurs, unambiguous relics of
some catastrophic calamity within the
tumor cell, a salient reminder of the
genomic abyss that opens when the
mechanisms that maintain chromosomal
integrity fail or are overridden. Indeed, so
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common is karyotypic mayhem in tumor
cells that many regard it as indispens-
able for the tumorigenic process, feeding
inchoate tumor cells with a never-ending
repertoire of selective advantages that
foster outgrowth of ever more malignant
and drug-resistant clones. It is now wide-
ly accepted that loss of genome integrity
represents the failure of checkpoint
machineries that would otherwise have
censored the offending cell. Moreover,
new genomic approaches have revealed
that differing tumor cells exhibit a bewil-
dering array of genetic lesions (Gray and
Collins, 2000), lending credence to the
notion that genome instability is an oblig-
ate feature of tumorigenesis.
Vafa et al. (2002) present a highly
provocative study offering a direct link
between activation of the ubiquitous Myc
oncoprotein and genome instability.They
show that ectopic activation of the Myc in
fibroblasts in vitro induces the rapid
onset of DNA damage, possibly through
the induction of reactive oxygen species
(ROS), a seeming by-product of Myc
activation. Although Myc can induce
apoptosis, an inherent ability thought to
be an important restraint to Myc onco-
genic potential, they see little sign of this.
Instead, Myc not only induces DNA dam-
age but, rather foolishly it seems, thwarts
the ability of p53 to induce an effective
checkpoint response: the combined
effect is to drive cells into an ineluctable
cell cycle with damaged DNA. In terms of
genome instability, this makes for a
heady brew, especially in vertebrates,
where the favored way of dealing with
broken pieces of DNA is to stick them
back together again by nonhomologous
end joining and hope for the best. The
ensuing loss of genome integrity, Vafa et
al. argue, propels the cell and its progeny
down the evolutionary road to neoplastic
Armageddon.
Evidence that Myc, and certain other
oncoproteins, might induce genome
instability has been slowly accumulating.
Early studies indicated that elevated Myc
promoted gene amplification in cell lines
(Mai et al., 1996), but Felsher and Bishop
were the first to show that Myc activation
directly induced the rapid accumulation
of chromosomal defects and aberrant
copy number in Rat-1 fibroblasts (Felsher
and Bishop, 1999). The lack of an opera-
tional ARF/MDM2/p53 pathway in such
immortalized rodent cells left open the
possibility that such genome havoc was
a peculiarity of established cell lines.
However, the dramatic data of Vafa et al.
confirm that Myc activation can induce
significant DNA damage in genetically
normal, primary human fibroblasts. If this
holds in vivo, it would provide a powerful
mechanism by which oncogene activa-
tion could accelerate tumor evolution
and progression.
However, this paper raises two
thorny but important issues. The first has
to do with how applicable these in vitro
data are to the situation in vivo. The sec-
ond has to do with how important
genome instability really is for tumor pro-
gression.
The reason why in vitro models (yes,
all of them!) need to be considered with
some caution is that there is clear evi-
dence that “standard” tissue culture con-
ditions exact a severe punishment on
cellular genomes. Perhaps the best evi-
dence for this is the rapid genome disor-
ganization that accompanies propaga-
tion of p53-deficient cells in vitro. Within
only a few passages, the vast majority of
explanted p53 KO fibroblasts exhibit
gross karyotypic abnormalities, including
polyploidy, aneuploidy, and chromoso-
mal abnormalities (Harvey et al., 1993).
This contrasts sharply with the stability of
genomes in somatic cells of p53 KO
mice in vivo, which underscores that loss
of p53 does not in itself cause genome
damage. We are left with the unpalatable
but inescapable conclusion that growth
in culture exposes cellular genomes to a
sleet of genotoxic insults that, without
the protective surveillance afforded by
p53, rapidly leads to degeneration of
genomic integrity. In rodent cells, the
genotoxic depredations of such “culture
shock” are widely acknowledged to be
the mechanism underlying “crisis,” the
growth barrier emplaced by upregulation
of the ARF tumor suppressor, which trig-
gers p53 stabilization and growth arrest
(Sherr and DePinho, 2000) and was long
conflated with human replicative senes-
cence. Unexpectedly, this tumor-sup-
pressive barrier seems not to arise in
human cells which, instead, encounter
the more formidable proliferative back-
stop of telomere erosion (DePinho,
2000).
There are several candidate culprits
for this culture shock including growth on
plastic, the high blue content of white flu-
orescent light, and the unremitting mito-
genic onslaught of fetal serum. But of
them all, the most probable suspect is
that pervasive, corrosive, and genotoxic
gas, oxygen. In vivo, somatic cells are
generally exposed to an oxygen tension
in the range 1%–2%, which is, incidently,
precisely the oxygen range over which
stabilization of the hypoxia response
transcription factor HIF1α is observed.
Standard culture conditions exceed nor-
mal oxygen exposure by 10-fold, so it is
rather provocative that Vafa et al. are
able to attribute their Myc-induced DNA
damage to reactive oxygen species and
specifically suppress the damage with
the oxido-protective reagent N-acetyl-
cysteine. Thus, although they attribute
their DNA damage specifically to Myc, it
is conceivable that any proliferative
process, whether induced by oncogenes
or normal mitogens, could elicit the same
DNA damage in such unphysiological
oxygen levels. It is also acknowledged
that c-Myc is a potent trigger of apopto-
sis, both in vitro and in vivo, and that this
apoptotic proclivity is greatly exacerbat-
ed by p53-dependent damage signals
(Evan and Vousden, 2001). This means
that even were the p53 growth arrest
response abrogated, the invariable fate
of such cells could nonetheless be their
expeditious p53-dependent apoptosis.
The only available studies of the
effects of activated Myc in vivo come
from mouse transgenic models, which
exhibit little evidence of Myc-induced
genomic instability. The recent elegant
lymphoma model of Schmitt et al. (2002)
demonstrates that the combination of c-
Myc and apoptosis suppressor Bcl-2 is
sufficient to drive advanced Eµ-myc lym-
phoma without ostensible genomic insta-
bility. Moreover, although loss of p53
confers similar acceleration of c-Myc-
induced lymphomagenesis, the genome
instability that arises seems to be an
irrelevant sideshow to the critical role of
p53 loss, which is to curtail c-Myc-
induced apoptosis. Likewise, switchable
c-Myc transgenic tumor models in both
skin and β cells (Pelengaris et al., 1999,
2002) indicate that despite acquiring
many aspects of advanced neoplasia,
such tumors remain absolutely depen-
dent upon sustained c-Myc for their
maintenance, suggesting no dramatic
acquisition of secondary lesions. One
important inference from such in vivo
studies is that apoptosis is a powerful
and inherent tumor-suppressive mecha-
nism that acts as a major fetter to the
oncogenic potential of c-Myc (Green and
Evan, 2002). As already discussed
above, therefore, it seems reasonable to
assume that even were c-Myc able to
inflict significant DNA damage, the
almost invariable outcome would be
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death of the affected cell.
More generally, there is now a fertile
and sometimes fractious dispute as to
the importance of genome instability in
tumorigenesis. On the one extreme,
some have argued aneuploidy is the fun-
damental mechanism of tumorigenesis,
with activated oncogenes and wrecked
tumor suppressors merely a sideshow to
distract gullible molecular biologists
(Duesberg, 1999). More mainstream,
however, is the important debate over
whether genome instability is a perva-
sive and sustained attribute of tumor
cells, perhaps driven by oncoproteins
like Myc, or rather a relic of some past
genomic mayhem  (such as telomere
erosion) that has long since stabilized
(DePinho, 2000). In this latter case,
genome instability would be the
sideshow to the underlying proliferative
and antiapoptotic lesions that drive the
inexorable proliferation and enforced
survival of the evolving tumor cell.
Defining a direct link between oncogenic
lesions and genomic instability would
certainly keep both camps happy: the
testing of intriguing studies like those of
Vafa et al. in animal models may settle
the matter once and for all.
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Thinking beyond the tumor cell: Nf1 haploinsufficiency 
in the tumor environment
Deletion of both copies of the Nf1 gene in Schwann cells combined with Nf1 heterozygosity in the tumor environment pro-
motes neurofibroma formation in mice.
Tumor cells in vivo do not grow in isolation
and are intimately associated with non-
neoplastic cells such as endothelial cells,
fibroblasts, and inflammatory cells.
Together, tumor cells and their neighbors
form a complex tissue mass in which a
network of heterotypic cell interactions
occurs (Hanahan and Weinberg, 2000).
The net balance between growth-promot-
ing and growth-inhibitory interactions like-
ly determines whether a given host envi-
ronment is permissive or resistant to
tumor formation. A thorough understand-
ing of these heterotypic cell interactions
may therefore provide the basis for novel
anticancer therapies aimed at increasing
the resistance of the host environment.
In a recent paper, Zhu and coworkers
focused on neurofibromas, benign tumors
of the peripheral nerve sheath, as models
for study of heterotypic cell interactions
(Zhu et al., 2002). Neurofibromas are
unique among tumors with respect to the
extent of their cellular heterogeneity.
Neurofibromas invariably contain all of the
cell types found in normal peripheral
nerves (axonal processes of neurons,
Schwann cells, perineurial cells, fibrob-
lasts, and mast cells) (Figure 1). The cel-
lular heterogeneity of neurofibromas is so
striking that some in the past argued that
these lesions were actually hyperplasias,
not tumors.
Neurofibromas are the major feature
of the common familial cancer syndrome
neurofibromatosis type 1 (NF1). Patients
with NF1 inherit a germline mutation in
one copy of the NF1 gene, which encodes
the protein neurofibromin, a member of
the Ras-specific GTPase-activating pro-
tein (RasGAP) family (Buchberg et al.,
1990; Xu et al., 1990). When a somatic
mutation eliminates the remaining wild-
type NF1 gene copy, tumor formation is
initiated. The fundamental problem with
NF1-deficient tumor cells is thought to be
that Ras, a key component of many
growth factor signaling pathways, is con-
stitutively activated, resulting in increased
cell proliferation and/or cell survival.
The first obstacle that Zhu and co-
workers had to overcome was to create a
tractable mouse model of neuro-
fibromas. While Nf1−/− mice die in
midgestation, Nf1+/− mice are cancer
prone, developing two tumors associat-
ed with NF1 (pheochromocytoma and
myeloid leukemia) but not neurofibro-
mas (Brannan et al., 1994; Jacks et al.,
1994). Based on the hypothesis that
somatic Nf1 mutation is the rate-limiting
step in neurofibroma formation in Nf1+/−
mice, Cichowski and coworkers created
chimeric mice partially composed of Nf1−/−
cells (Cichowski et al., 1999). Nearly all of
these mice develop numerous neurofibro-
